Citius Oncology (CTOR) Net Shares Issued and Repurchased (2024 - 2025)
Citius Oncology's (CTOR) quarterly Net Shares Issued and Repurchased came in at $5.8 million in Q3 2025, up 3733.33% year-over-year from $150000.0 in Q3 2024, and little changed quarter-over-quarter from $5.8 million in Q4 2024.
Powered by 
Analysis
Citius Oncology (CTOR) Net Shares Issued and Repurchased (2024 - 2025) Analysis & Trends
Citius Oncology (CTOR) has reported Net Shares Issued and Repurchased for 2 consecutive years, with $5.8 million the latest figure, recorded in Q3 2025.
- On a quarterly basis, Net Shares Issued and Repurchased rose 3733.33% year-over-year to $5.8 million in Q3 2025; TTM through Sep 2025 was $5.8 million, a 3733.33% increase from a year earlier, with the FY2025 full-year figure at $5.8 million, up 3733.33% from the prior year.
- Net Shares Issued and Repurchased was $5.8 million for Q3 2025 at Citius Oncology, roughly flat from $5.8 million in the prior quarter.
- Over five years, Net Shares Issued and Repurchased peaked at $5.8 million in Q4 2024 and troughed at $150000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Citius Oncology | 101.41 Mn | 101.41 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 5.75 Mn |
| Dec 31, 2024 | 5.75 Mn |
| Sep 30, 2024 | 150,000.00 |